Search results for "vaccination"

showing 10 items of 660 documents

Determinants of European parents' decision on the vaccination of their children against measles, mumps and rubella: A systematic review and meta-anal…

2016

ABSTRACT Low measles, mumps and rubella (MMR) immunization levels in European children highlight the importance of identifying determinants of parental vaccine uptake to implement policies for increasing vaccine compliance. The aim of this paper is to identify the main factors associated with partial and full MMR vaccination uptake in European parents, and combine the different studies to obtain overall quantitative measures. This activity is included within the ESCULAPIO project, funded by the Italian Ministry of Health. ORs and CIs were extracted, sources of heterogeneity explored and publication bias assessed. Forty-five papers were retrieved for the qualitative study, 26 of which were i…

ParentsHealth Knowledge Attitudes PracticePediatricsmedicine.medical_specialtyMeasles-Mumps-Rubella Vaccinedeterminant; measles; mumps and rubella; parents; uptake; vaccine; Immunology and Allergy; Immunology; PharmacologyImmunologyReviewdeterminantSettore MED/42 - Igiene Generale E ApplicataMMR vaccineRubellaMeasles03 medical and health sciences0302 clinical medicinevaccine030225 pediatricsHumansmeaslesmeasleImmunology and AllergyMedicinemumps and rubella030212 general & internal medicineMumpsRubellaPharmacologyPracticebusiness.industryHealth KnowledgeVaccinationPublication biasPatient Acceptance of Health Caremedicine.diseaseEuropeVaccinationparentdeterminant; measles; mumps and rubella; parents; uptake; vaccine; Europe; Health Knowledge Attitudes Practice; Humans; Measles; Measles-Mumps-Rubella Vaccine; Mumps; Patient Acceptance of Health Care; Rubella; Vaccination; ParentsAttitudesuptakeMeta-analysisMarital statusbusinessMeasles-Mumps-Rubella VaccineDemographyHuman Vaccines & Immunotherapeutics
researchProduct

Post vaccine acute disseminated encephalomyelitis as the first manifestation of chromosome 22q11.2 deletion syndrome in a 15-month old baby: a case r…

2014

We describe a case of a 15-month-old female child admitted to our hospital because of fever, rash, neurological signs (oscillation between states of irritability and drowsiness), palpebral edema and drooping eyelid, appeared 10 days after the vaccination for measles, mumps and rubella. Brain MRI images showed multiple bilateral hyperintense lesions in the white matter typical of acute disseminated encephalomyelitis (ADEM), an autoimmune demyelinating disorder with inflammatory lesions of the central nervous system, due to viral antigens or vaccines. In the mean time, because of patient's vague phenotypic manifestations, suggestive of a genetic defect, array comparative genomic hybridization…

Pathologymedicine.medical_specialtyChromosomes Human Pair 22IrritabilityMeaslesRubellaDiGeorge syndromeAcute disseminated encephalomyelitismedicineDiGeorge SyndromeHumansComparative Genomic HybridizationADEM; DiGeorge syndromeGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryEncephalomyelitis Acute DisseminatedVaccinationPublic Health Environmental and Occupational HealthBrainInfantmedicine.diseaseRashDermatologyMagnetic Resonance ImagingVaccinationInfectious Diseasesmedicine.anatomical_structureAcute disseminated encephalomyelitisMolecular MedicineFemaleEyelidmedicine.symptombusinessMeasles-Mumps-Rubella Vaccine
researchProduct

Clinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria and tetanus toxoids for primary vaccination in 22,505 infa…

1996

Abstract OBJECTIVES: To assess the safety and tolerability of 12 lots of SmithKline Beecham Biologicals' diphtheria-tetanus-tricomponent acellular pertussis vaccine (DTaP) in a large cohort of 22,000 vaccinees, with detailed analyses of reactivity, immunogenicity, and immune response to pertussis toxin in subsets. METHODS: In a prospective, double-blind, multicenter trial in Germany, 22,505 healthy infants received three vaccinations of DTaP at age 3, 4, and 5 months. Serious adverse events were followed for 1 month after each vaccination, and neurologic events for 1 year or longer. Serum IgG antibodies were assayed before vaccination and 1 month after vaccination. RESULTS: After 67,000 dos…

Pediatricsmedicine.medical_specialtyFeverFilamentous haemagglutinin adhesinDouble-Blind MethodSeizuresGermanyMedicineHumansProspective StudiesAdverse effectWhooping coughDiphtheria-Tetanus-Pertussis VaccineEpilepsybusiness.industryTetanusDiphtheriaIncidenceInfantSudden infant death syndromemedicine.diseaseVaccinationPediatrics Perinatology and Child HealthImmunologyPertactinbusinessSpasms InfantileSudden Infant DeathThe Journal of pediatrics
researchProduct

Varicella vaccination as useful strategy for reducing the risk of varicella-related hospitalizations in both vaccinated and unvaccinated cohorts (Ita…

2020

The present study summarizes evidences of the impact that varicella vaccination (VV) introduction and coverage can have on varicella attributable hospitalization rates.A retrospective observational study was carried out by considering hospital discharge records and VV coverage at 24 months collected from 2003 to 2018 by the Italian Ministry of Health. All hospitalizations records reporting an ICD-9 CM 052.X code as the principal diagnosis or any of the five secondary diagnoses were considered as related to varicella. The hospitalization rate reduction was evaluated by calculating average annual percent change (AAPC) through joint-point analysis.Hospitalization rates showed a decreasing tren…

Pediatricsmedicine.medical_specialtyHerpesvirus 3 Human030231 tropical medicineVaricella vaccinationChickenpox Vaccine03 medical and health sciences0302 clinical medicineChickenpoxmedicineHospital dischargeHumans030212 general & internal medicineChildAgedGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryPublic healthVaccinationPublic Health Environmental and Occupational HealthInfantRetrospective cohort studyAnnual Percent ChangeVaccinationHospitalizationInfectious DiseasesItalyMolecular MedicineChristian ministryPrincipal diagnosisbusinessVaricella vaccination.Vaccine
researchProduct

Precise reply and clarifications on behalf of Sicilian Public Health Authorities to the case report published by La Rosa and collegues

2016

The intussusception is one of the most frequent causes of occlusive syndrome in infants and in children.1 The mesenteric lymphadenopathy, wich is very rare post rotavirus vaccination, can cause intussusception,2-5 especially in genetically predisposed individuals.6 There is an association between intussusception and some classes of genotype.7-9 Two infants aged 3 months, vaccinated against rotavirus. After about a week, one of the 2 identical infants presented inconsolable crying, vomiting, loose stools mixed with blood, and was diagnosed with bowel obstruction with intussusception. He was operated in urgency. After a few hours, his brother presented vomiting, and was admitted to our Hospit…

Pediatricsmedicine.medical_specialtyImmunologyTwinsCase ReportPublic administrationRotavirus vaccinationSettore MED/42 - Igiene Generale E ApplicataRotavirus Infections03 medical and health sciencesHealth services0302 clinical medicine030225 pediatricsMedicineHumansImmunology and Allergy030212 general & internal medicineImmunization scheduleSicilyintussusceptionPharmacologybusiness.industryImmunization ProgramsPublic healthHealth PolicyRotavirus VaccinesInfantrotavirus vaccinationlanguage.human_languageClinical PracticeImmunization schedule; intussusception; pediatric population; rotavirus vaccination; Immunology and Allergy; Immunology; PharmacologylanguageMass vaccinationbusinessIdentical twinsSicilianpediatric populationPediatric population
researchProduct

Impact of universal vaccination against varicella in Italy: Experiences from eight Italian Regions.

2014

In Italy, the introduction of Universal Varicella Vaccination (UVV) has been decided but postponed, as a national programme, until 2015, when data from Regions which have already implemented it will be available. Starting from 2003, eight Italian Regions (Basilicata, Calabria, Friuli Venezia Giulia, Apulia, Sardinia, Sicily, Tuscany and Veneto) have progressively introduced UVV, in their immunization programme, with different schedules in children aged 13-15 months and 5-6 years, currently a two-dose schedule is adopted by all Regions. In June 2013, an Interregional Group on Varicella Vaccination (IGVV) has been established in order to assess the effectiveness of varicella vaccination with …

Pediatricsmedicine.medical_specialtyImmunologyadverse events following varicella immunizationVaricellaSettore MED/42 - Igiene Generale E ApplicataEnvironmental healthmedicineImmunology and AllergyHealth policyChickenpox VaccinePharmacologyChickenpoxbusiness.industryIncidence (epidemiology)immunization coverageHealth services researchUniversal Varicella VaccinationnotificationsVaricella; Universal Varicella Vaccination; Notifications; Hospitalizations; Immunization coverage; Adverse effectsmedicine.diseaseVaccinationImmunizationVaccination coverageUniversal Varicella Vaccination; Varicella; adverse events following varicella immunization; hospitalizations; immunization coverage; notificationsbusinesshospitalization
researchProduct

Transient suppression of atopy in early childhood is associated with high vaccination coverage.

2003

Objective. To analyze prevalences of allergic sensitization and atopic disease in relation to vaccination coverage. Methods. A German atopy risk-enhanced birth cohort of 1314 neonates who were born in 1990 in 5 German cities was studied. A total of 943 children participated in the follow-up visit at 5 years of age. Atopic symptoms and diagnoses (derived from structured interviews), total serum immunoglobulin E, and specific immunoglobulin E against 9 common allergens (CAP Radio-Allergo-Sorbent Test Fluoro-Enzyme Immunoassay) were evaluated. Children were grouped into dose percentiles according to cumulative doses of any vaccine given up to 5 years of age (<10%, 0–11 doses; 10%–50%, 1…

Pediatricsmedicine.medical_specialtyPercentileDose-Response Relationship ImmunologicImmunoglobulin EDermatitis AtopicAtopyRadioallergosorbent TestHypersensitivityMedicineHumansEarly childhoodSensitizationAsthmaVaccinesbiologybusiness.industryImmunization ProgramsVaccinationInfant NewbornInfantAtopic dermatitisImmunoglobulin Emedicine.diseaseAsthmamedicine.anatomical_structureVaccination coverageChild PreschoolPediatrics Perinatology and Child Healthbiology.proteinbusinessFollow-Up StudiesPediatrics
researchProduct

Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combi…

2006

Abstract Background To evaluate immunogenicity, reactogenicity, and safety of a hexavalent combination vaccine diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus- Haemophilus influenzae type b (DTPa-HBV-IPV/Hib) when coadministered with a 7-valent pneumococcal conjugate vaccine (PCV7). Methods Infants received either a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus- H. influenzae type b vaccine concomitantly with PCV7 or DTPa-HBV-IPV/Hib alone infants were vaccinated at 2, 3 and 4 months (primary immunization) and 12–15 months of age (booster dose). Local and systemic reactions and adverse events were monitored following each do…

Pediatricsmedicine.medical_specialtyPopulationBooster doseDiphtheria-Tetanus-acellular Pertussis Vaccinescomplex mixturesPneumococcal conjugate vaccinePneumococcal VaccinesmedicineHumansHepatitis B VaccinesVaccines CombinededucationWhooping coughBacterial CapsulesHaemophilus Vaccineseducation.field_of_studyReactogenicityGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryTetanusDiphtheriaPolysaccharides BacterialPublic Health Environmental and Occupational HealthInfantmedicine.diseaseVaccinationPoliovirus Vaccine InactivatedInfectious DiseasesImmunologyAntibody FormationMolecular MedicineImmunizationbusinessmedicine.drugVaccine
researchProduct

The potential for pneumococcal vaccination in Hajj pilgrims: expert opinion.

2013

Hajj is the annual pilgrimage to Mecca in the Kingdom of Saudi Arabia, and is one of the largest mass gathering events in the world. Acute respiratory tract infections are very common during Hajj, primarily as a result of close contact among pilgrims, intense congestion, shared accommodation and air pollution. A number of vaccines are (or have been) recommended for Hajj pilgrims in recent years. Several additional vaccines could significantly reduce the morbidity and mortality at Hajj and should be considered in health recommendations for pilgrims. Pneumococcal vaccines (particularly for those aged >65 years) are widely available, and have been shown to reduce the burden of disease associat…

Pediatricsmedicine.medical_specialtyPopulationSaudi ArabiaIslamPneumococcal conjugate vaccinePneumococcal InfectionsPneumococcal VaccinesEnvironmental healthMass gatheringMedicineTravel medicineHumanseducationeducation.field_of_studyTravelRespiratory tract infectionsbusiness.industryReligion and MedicinePublic Health Environmental and Occupational HealthPneumococcal polysaccharide vaccineVaccinationInfectious DiseasesCrowdingHajjbusinessTravel Medicinemedicine.drugTravel medicine and infectious disease
researchProduct

Age- and Sex-Graded Data Evaluation of Vaccination Reactions after Initial Injection of the BNT162b2 mRNA Vaccine in a Local Vaccination Center in Ge…

2021

A high vaccination rate of older and particularly chronically ill people against coronavirus disease-2019 (COVID-19) is likely one of the most important factors in containing the pandemic. When Germany’s vaccination campaign started on December 2020, vaccination prioritization was initially carried out starting with older population groups. Side effect rates in 1065 individuals who had received the first dose of the messenger ribonucleic acid (mRNA) vaccine BNT162b2 Tozinameran from BioNTech/Pfizer three weeks earlier were examined retrospectively. An age- and gender-graded data analysis showed clear age and gender differences with regard to vaccine-related adverse effects. In 77% of all in…

Pediatricsmedicine.medical_specialtySide effectCoronavirus disease 2019 (COVID-19)COVID-19 vaccinationImmunologyage- and sex-graded data evaluationArticleHerd immunityImmunityDrug DiscoveryPandemicmedicinePharmacology (medical)Adverse effectPharmacologyvaccination strategymRNA vaccine BNT162b2business.industryRVaccinationInfectious DiseasesPopulation studyMedicinebusinessvaccination side effectsVaccines
researchProduct